Imuldosa

Ustekinumab, the active ingredient in Imuldosa, is a monoclonal antibody presented as a sterile solution for intravenous and subcutaneous use. It modulates immune activity and is indicated for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis in adult patients with moderate to severe disease.

GNH USA supplies Imuldosa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved product for global distribution throughout.

Imuldosa (ustekinumab) targets the interleukin‑12/23 pathway in immune‑mediated inflammatory diseases.

- Plaque psoriasis: reduces skin lesions, scaling and erythema, leading to improved Psoriasis Area and Severity Index scores. - Psoriatic arthritis: improves joint pain, swelling and stiffness, and helps prevent radiographic progression. - Crohn's disease: induces clinical remission and maintains response in moderate to severe intestinal inflammation. - Ulcerative colitis: achieves clinical remission and promotes mucosal healing in adult patients with active disease.

Ustekinumab may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Injection site reactions: pain, redness, or swelling. - Upper respiratory infections: nasopharyngitis or mild sinusitis. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Infections: opportunistic infections such as tuberculosis or fungal infections. - Allergic reactions: anaphylaxis or severe hypersensitivity. - Malignancies: potential increased risk of certain cancers.

When prescribing ustekinumab, clinicians should consider several precautionary measures to ensure patient safety.

- Infection screening: evaluate for active tuberculosis and chronic infections before initiation. - Vaccination status: administer required vaccines prior to therapy, avoiding live vaccines during treatment. - Monitoring: regularly assess for signs of infection, malignancy, and cardiovascular events. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Concomitant immunosuppression: exercise caution when combined with other immunosuppressive agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ustekinumab can interact with other medicines, primarily affecting immune function or infection risk.

Major Interactions (Avoid): - Live vaccines: concurrent use may cause severe infection. - Antifungal agents: may increase risk of opportunistic infections when combined.

Moderate Interactions (Monitor Closely): - Other biologics: combined immunosuppression may heighten infection risk. - Systemic corticosteroids: may augment immunosuppressive effect. - Immunomodulators (e.g., methotrexate): monitor for additive toxicity.